Literature DB >> 28448787

Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer.

An-Quan Shang1,2, Jian Wu3, Feng Bi4, Yu-Jie Zhang1, Lei-Rong Xu3, Ling-Ling Li3, Fei-Fei Chen3, Wei-Wei Wang5,6, Jian-Jun Zhu3, You-Yi Liu7.   

Abstract

OBJECTIVE: The study aims to explore the relationship between expressions of HER2 and JAK/STAT3-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer (OC).
METHODS: A total of 136 OC patients were collected. Immunohistochemistry was applied to measure the expressions of STAT3, p-STAT3, SOCS3, HER2 and p-HER2 in the tumor tissues and adjacent normal tissues. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the mRNA expressions of HER2, SOCS3 and STAT3 and western blotting was applied for protein expressions of HER2, p-HER2, SOCS3, STAT3 and p-STAT3 in the tumor tissues and adjacent normal tissues. Flow cytometry was used for the cell apoptosis in the blank, afatinib (A), ruxolitinib (R) and afatinib + ruxolitinib (A + R) groups. Follow-up was performed to explore relationship of HER2, SOCS3, and STAT3 expressions with survival time of OC patients.
RESULTS: HER2, p-HER2, STAT3, and p-STAT3 expressions were higher while SOCS3 expression was lower in the tumor tissues. The positive expressions of STAT3, HER2, p-HER2 and p-STAT3 were lower while the positive expression of SOCS3 was higher in the adjacent normal tissues. The expressions of HER2, SOCS3, and p-STAT3 were associated with clinical stage and lymph node metastasis (LNM), and STAT3 expression has correlation with histological grade and LNM. The mRNA and protein expressions of HER2, STAT3 and p-STAT3 in the tumor tissues were higher than those in the adjacent normal tissues, but SOCS3 expression was significantly decreased. The positive expressions of HER2, p-HER2 and STAT3, the negative expression of SOCS3 and pathological stages were important risk factors for the prognosis of patients with OC.
CONCLUSION: Our study showed that the expressions of HER2, STAT3, and SOCS3 are associated with the progression of OC, and higher expressions of HER2 and STAT3 and lower expression of SOCS3 predict poor prognosis of OC.

Entities:  

Keywords:  Clinicopathological features; human epidermal growth factor receptor 2; ovarian cancer; prognosis; signal transducer and activator of transcription 3; signaling pathway; suppressors of cytokine signaling 3

Mesh:

Substances:

Year:  2017        PMID: 28448787      PMCID: PMC5499756          DOI: 10.1080/15384047.2017.1310343

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  34 in total

1.  Phosphorylation of signal transducer and activator of transcription 3 in soft tissue leiomyosarcoma is associated with a better prognosis.

Authors:  Nokitaka Setsu; Kenichi Kohashi; Makoto Endo; Hidetaka Yamamoto; Sadafumi Tamiya; Yusuke Takahashi; Yuichi Yamada; Takeaki Ishii; Shuichi Matsuda; Ryohei Yokoyama; Yukihide Iwamoto; Yoshinao Oda
Journal:  Int J Cancer       Date:  2012-06-20       Impact factor: 7.396

2.  Combination of AG490, a Jak2 inhibitor, and methylsulfonylmethane synergistically suppresses bladder tumor growth via the Jak2/STAT3 pathway.

Authors:  Youn Hee Joung; Yoon Mi Na; Young Bum Yoo; Pramod Darvin; Nipin Sp; Dong Young Kang; Sang Yoon Kim; Hong Sup Kim; Yoon Hee Choi; Hak Kyo Lee; Kyung Do Park; Byung Wook Cho; Heui Soo Kim; Jong Hwan Park; Young Mok Yang
Journal:  Int J Oncol       Date:  2014-01-08       Impact factor: 5.650

3.  Optimal first-line treatment in ovarian cancer.

Authors:  F A Raja; N Chopra; J A Ledermann
Journal:  Ann Oncol       Date:  2012-09       Impact factor: 32.976

4.  A phase 3 trial of bevacizumab in ovarian cancer.

Authors:  Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

5.  Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor κB signaling in glioblastoma cancer stem cells regulates the Notch pathway.

Authors:  Jo Meagan Garner; Meiyun Fan; Chuan He Yang; Ziyun Du; Michelle Sims; Andrew M Davidoff; Lawrence M Pfeffer
Journal:  J Biol Chem       Date:  2013-07-31       Impact factor: 5.157

6.  Lymph node metastasis is mediated by suppressor of cytokine signaling-3 in gastric cancer.

Authors:  Jingyu Deng; Xuguang Jiao; Honggen Liu; Liangliang Wu; Rupeng Zhang; Baogui Wang; Yi Pan; Xishan Hao; Han Liang
Journal:  Tumour Biol       Date:  2013-07-04

7.  [Ovarian cancer. I. Epidemiology, symptoms, FIGO staging].

Authors:  M Nowak; M Szpakowski; A Malinowski; A Wieczorek; A Szpakowski; Z Raczkowska; G Maciołek-Blewniewska; J Laskowski; W Budźko; D Kolasa
Journal:  Ginekol Pol       Date:  2000-09       Impact factor: 1.232

8.  Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation.

Authors:  Hsien-Neng Huang; Ying-Cheng Chiang; Wen-Fang Cheng; Chi-An Chen; Ming-Chieh Lin; Kuan-Ting Kuo
Journal:  Mod Pathol       Date:  2014-08-01       Impact factor: 7.842

9.  Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer.

Authors:  Yunlang Cai; Jingmei Wang; Lin Zhang; Di Wu; Dandan Yu; Xiaoqiang Tian; Jun Liu; Xinru Jiang; Yang Shen; Lihua Zhang; Mulan Ren; Peilin Huang
Journal:  Med Oncol       Date:  2014-11-30       Impact factor: 3.064

10.  Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease.

Authors:  J Zidan; I Dashkovsky; C Stayerman; W Basher; C Cozacov; A Hadary
Journal:  Br J Cancer       Date:  2005-09-05       Impact factor: 7.640

View more
  23 in total

1.  [Role of cytokine signal suppressor 3 in the regulatory mechanism of colon cancer invasion and proliferation].

Authors:  Zhu Hong; Xipeng Zhang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-01-30

2.  JAK/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance.

Authors:  Hatem E Sabaawy; Bríd M Ryan; Hossein Khiabanian; Sharon R Pine
Journal:  Carcinogenesis       Date:  2021-12-31       Impact factor: 4.741

Review 3.  Advances in the Application of Radionuclide-Labeled HER2 Affibody for the Diagnosis and Treatment of Ovarian Cancer.

Authors:  Xianwen Hu; Dandan Li; Yujie Fu; Jiashen Zheng; Zelong Feng; Jiong Cai; Pan Wang
Journal:  Front Oncol       Date:  2022-06-15       Impact factor: 5.738

4.  The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies.

Authors:  Hui Luo; Xiaohui Xu; Miaomiao Ye; Bo Sheng; Xueqiong Zhu
Journal:  PLoS One       Date:  2018-01-30       Impact factor: 3.240

Review 5.  Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence.

Authors:  Qiao Wang; Hongling Peng; Xiaorong Qi; Min Wu; Xia Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-07-29

6.  Transcriptional repression of human epidermal growth factor receptor 2 by ClC-3 Cl- /H+ transporter inhibition in human breast cancer cells.

Authors:  Mayu Fujimoto; Hiroaki Kito; Junko Kajikuri; Susumu Ohya
Journal:  Cancer Sci       Date:  2018-07-28       Impact factor: 6.716

7.  HER2 decreases drug sensitivity of ovarian cancer cells via inducing stem cell-like property in an NFκB-dependent way.

Authors:  Wenxiang Wang; Yuxia Gao; Jing Hai; Jing Yang; Shufeng Duan
Journal:  Biosci Rep       Date:  2019-03-19       Impact factor: 3.840

8.  Targeting HER2 in patient-derived xenograft ovarian cancer models sensitizes tumors to chemotherapy.

Authors:  Faye R Harris; Piyan Zhang; Lin Yang; Xiaonan Hou; Konstantinos Leventakos; Saravut J Weroha; George Vasmatzis; Irina V Kovtun
Journal:  Mol Oncol       Date:  2018-12-21       Impact factor: 6.603

Review 9.  Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer.

Authors:  Shuna Liu; Ming Wu; Fang Wang
Journal:  J Cancer       Date:  2021-05-13       Impact factor: 4.207

10.  SPTBN1 suppresses the progression of epithelial ovarian cancer via SOCS3-mediated blockade of the JAK/STAT3 signaling pathway.

Authors:  Mo Chen; Jia Zeng; Shuyi Chen; Jiajia Li; Huijie Wu; Xuhui Dong; Yuan Lei; Xiuling Zhi; Liangqing Yao
Journal:  Aging (Albany NY)       Date:  2020-06-08       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.